Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001437749-26-005889

Chief Scientific Officer sold 8,124 shares at an average $16.02 ($130,164)

  • Chief Scientific Officer acquired 8,124 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lorrain Daniel S. · Chief Scientific Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-02-24 Exercise or conversion : show line 1 in the form 10b5-1 +4,300 $1.01 $4,343 160,352 D
2026-02-24 Sale : show line 2 in the form 10b5-1 −4,300 $16.03 $68,936 156,052 D
2026-02-25 Exercise or conversion : show line 3 in the form 10b5-1 +3,824 $1.01 $3,862 159,876 D
2026-02-25 Sale : show line 4 in the form 10b5-1 −3,824 $16.01 $61,228 156,052 D
Open-market sales · 8,124 sh · avg $16.02 · $130,164

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-02-24 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) −4,300 71,130 D
2026-02-25 Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (right to buy) −3,824 67,306 D
Loading xslF345X05/rdgdoc.xml…